Development of fourth generation ABC inhibitors from natural products: A novel approach to overcome cancer multidrug resistance

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 5, 2015, Pages 605-615

  Karthikeyan, Subburayan ^a   Hoti, Sugeerappa Laxmanappa ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

ABC transporters; Chemotherapy; Multidrug resistance; Natural products; Overexpression

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER INHIBITOR; ACACETIN; ADENOSINE TRIPHOSPHATASE; ALKALOID DERIVATIVE; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CURCUMIN; CYCLOSPORIN A; DOFEQUIDAR; ELACRIDAR; FLAVONOID; GUANIDINE ALKALOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LANIQUIDAR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PHOSPHOGLYCOPROTEIN; PLANT MEDICINAL PRODUCT; POLYPHENOL; QUASSINOID DERIVATIVE; QUININE; RESVERATROL; TARIQUIDAR; TARIQUITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR; BIOLOGICAL PRODUCT;

ARTICLE; BINDING AFFINITY; BIODIVERSITY; CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; CLINICAL EFFECTIVENESS; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL PRODUCTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 84930719130     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150113103439     Document Type: Article

References (119)

1. Stewart, B.W.; Wild, C.P. World Cancer Report; Lyon, France: International Agency for Research on Cancer; 2014.
2. Lafon-Hughes, L.; Di Tomaso, M.V.; Mendez-Acuna, L.; Martınez-Lopez, W. Chromatin-remodelling mechanisms in cancer. Mutat. Res., 2008, 658, 191-214.
3. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012; Lyon, France: International Agency for Research on Cancer, 2012.
4. Huang, X.C.; Sun, Y.L.; Salim, A.A.; Chen, Z.S.; Capon, R.J. Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Biochem. Pharmacol., 2013, 85, 1257-1268.
5. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1991, 39, 361-398.
6. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
7. Ford, J.M.; Hait, W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 1990, 42, 155-199.
8. Klein, I.; Sarkadi, B.; Varadi, A. An inventory of the human ABC proteins. Biochim. Biophys. Acta, 1999, 1461, 237-262.
9. Dean, M.; Allikmets, R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr., 2001, 33, 475-479.
10. Ueda, K. ABC proteins protect the human body and maintain optimal health. Biosci. Biotechnol. Biochem., 2011, 75, 401-409.
11. Degorter, M.K.; Xia, C.Q.; Yang, J.J.; Kim, R.B. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 249-273.
12. Stanley, L.A.; Horsburgh, B.C.; Ross, J.; Scheer, N.; Wolf, C.R. Drug transporters: Gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab. Rev., 2009, 41, 27-65.
13. Litman, T.; Druley, T.E.; Stein, W.D.; Bates, S.E. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci., 2001, 58, 931-959.
14. Riordan, J.R.; Ling, V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem., 1979, 254, 12701-12705.
15. Hyde, S.C.; Emsley, P.; Hartshorn, M.J.; Mimmack, M.M.; Gileadi, U.; Pearce, S.R.; Gallagher, M.P.; Gill, D.R.; Hubbard, R.E.; Higgins, C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 1990, 346, 362-365.
16. Loo, T.W.; Clarke, D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol., 2005, 206, 173-185.
17. Cordon-Cardo, C.; O’Brien, J.P.; Boccia, J.; Casals, D.; Bertino, J.R.; Melamed, M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 1990, 38, 1277-1287.
18. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in p388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 1981, 41, 1967-1972.
19. Krishna, R.; Mayer, L.D. Modulation of P-glycoprotein (P-gp) mediated multidrug resistance (MDR) using chemosensitizers: Recent advances in the design of selective MDR modulators. Curr. Med. Chem. Anticancer Agents, 2001, 1, 163-174.
20. Fujiyama, K.; Palacpac, N.Q.; Sakai, H.; Kimura, Y.; Shinmyo, A.; Yoshida, T.; Seki, T. In vivo conversion of a glycan to human compatible type by transformed tobacco cells. Biochem. Biophys. Res. Commun., 2001, 289, 553-557.
21. Klinkhammer, W.; Muller, H.; Globisch, C.; Pajeva, I.K.; Wiese, M. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorg. Med. Chem., 2009, 17, 2524-2535.
22. Thomas, H.; Coley, H.M. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting Pglycoprotein. Cancer Control, 2003, 10, 159-165.
23. Szakacs, G.; Varadi, A.; Ozvegy-Laczka, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today, 2008, 13, 379-393.
24. Higgins, C.F. ABC transporters: From microorganisms to man. Annu. Rev. Cell Biol., 1992, 8, 67-113.
25. Brevig, T.; Kruhne, U.; Kahn, R.A.; Ahl, T.; Beyer, M.; Pedersen, L.H. Hydrodynamic guiding for addressing subsets of immobilized cells and molecules in microfluidic systems. BMC Biotechnol., 2003, 3, 1-10.
26. Sodani, K.; Patel, A.; Kathawala, R.J.; Chen, Z.S. Multidrug resistance associated proteins in multidrug resistance. Chin. J. Cancer, 2012, 31, 58-72.
27. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5, 219-234.
28. Zhou, S.F.; Wang, L.L.; Di, Y.M.; Xue, C.C.; Duan, W.; Li, C.G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 2008, 15, 1981-2039.
29. Bates, S.E.; Robey, R.; Miyake, K.; Rao, K.; Ross, D.D.; Litman, T. The role of half-transporters in multidrug resistance. J. Bioenerg. Biomembr., 2001, 33, 503-511.
30. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci., 1998, 95, 15665-15670.
31. Mao, Q.; Unadkat, J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J., 2005, 7, 118-133.
32. Krishnamurthy, P.; Schuetz, J.D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 381-410.
33. Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.; Cristensen, B.; Brangi, M. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res., 1999, 59, 8-13.
34. Nakanishi, T.; Doyle, L.A.; Hassel, B.; Wei, Y.; Bauer, K.S.; Wu, S.; Pumplin, D.W.; Fang, H.B. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of xenopus laevis. Mol. Pharmacol., 2003, 64, 1452-1462.
35. Volk, E.L.; Farley, K.M.; Wu, Y.; Li, F.; Robey, R.W.; Schneider, E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 2002, 62, 5035-5040.
36. Ross, D.D.; Yang, W.; Abruzzo, L.V.; Dalton, W.S.; Schneider, E.; Lage, H.; Dietel, M.; Greenberger, L.; Cole, S.P.; Doyle, L.A. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst., 1999, 91, 429-433.
37. Robert, J.; Jarry, C. Multi drug resistance reversal agents. J. Med.Chem., 2003, 46, 4805-4817.
38. Friedenberg, W.R.; Rue, M.; Blood, E.A.; Dalton, W.S.; Shustik, C.; Larson, R.A.; Sonneveld, P.; Greipp, P.R. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group. Cancer, 2006, 106, 830-838.
39. Tranchand, B.; Catimel, G.; Lucas, C.; Sarkany, M.; Bastian, G.; Evene, E.; Guastalla, J.P.; Negrier, S.; Rebattu, P.; Dumortier, A.; Foy, M.; Grossin, F.; Mazier, B.; Froudarakis, M.; Barbet, N.; Clavel, M.; Ardiet, C. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemother. Pharmacol., 1998, 41, 281-291.
40. O’Connor, R.; O'Leary, M.; Ballot, J.; Collins, C.D.; Kinsella, P.; Mager, D.E.; Arnold, R.D.; Driscoll, L.; Larkin, A.; Kennedy, S.; Fennelly, D.; Clynes, M.; Crown, J. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein 1 (MRP1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharmacol., 2007, 59, 79-87.
41. Kuppens, I.E.L.M.; Witteveen, E.O.; Jewell, R.C.; Radema, S.A.; Paul, E.M.; Mangum, S.G.; Beijnen, J.H.; Voest, E.E.; Schellens, J.H. A Phase I, randomized, open-label, parallel-cohort, dosefinding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res., 2007, 13, 3276-3285.
42. Fox, E.; Bates, S.E. Tariquidar (XR9576): P-glycoprotein drug effluxes pump inhibitor. Exp. Rev. Anticancer Ther., 2007, 7, 447-459.
43. Morschhauser, F.; Zinzani, P.L.; Burgess, M.; Sloots, L.; Bouafia, F.; Dumontet, C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk. Lymphoma, 2007, 48, 708-715.
44. Van Zuylen, L.; Sparreboom, A.; Van Der Gaast, A.; Van der Burg, M.E.; Van Beurden, V.; Bol, C.J.; Woestenborghs, R.; Palmer, P.A. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. J. Clin. Cancer Res., 2000, 6, 1365-1371.
45. Saeki, T.; Nomizu, T.; Toi, M.Y.; Noguchi, S.; Kobayashi, T.; Asaga, T.; Minami, H.; Yamamoto, N.; Aogi, K.; Keda, T.; Ohashi, Y.; Sato, W.; Tsuruo, T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J. Clin. Oncol., 2007, 25, 411-417.
46. Oldham, R. Safety and efficacy study of CBT-1 and paclitaxel with carboplatin in patients with advanced inoperable non-small cell lung cancer. Available at: Clinical trial. gov 2007.
47. Chi, K.N.; Chia, S.K.; Dixon, R.; Newman, M.J.; Wacher, V.J.; Sikic, B.; Gelmon, K.A. A phase I pharmacokinetic study of the Pglycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest. New Drugs, 2005, 23, 311-315.
48. Fracasso, P.M.; Goldstein, L.J.; De Alwis, D.P.; Rader, J.S.; Arquette, M.A.; Goodner, S.A.; Wright, L.P.; Fears, C.L.; Gazak, R.J.; Andre, V.A.; Burgess, M.F.; Slapak, C.A.; Schellens, J.H. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin. Cancer Res., 2004, 10, 7220-7228.
49. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theriault, R.; Booser, D.; Symmans, F.W.; Wong, F.; Blumenschein, G.; Fleming, D.R.; Rouzier, R.; Boniface, G.; Hortobagyi, G.N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104, 682-691.
50. Loa, Y.L.; Wanga, W.; Hob, C.T. 7,3,4-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicol., 2012, 302, 221-232.
51. Imai, Y.; Tsukahara, S.; Asada, S.; Sugimoto, Y. Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res., 2004, 64, 4346-4352.
52. Chearwae, W.; Shukla, S.; Limtrakul, P.; Ambudkar, S.V. Modulation of the function of the multidrug resistance-linked ATPbinding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., 2006, 5, 1995-2006.
53. Limtrakul, P, Chearwae, W.; Shukla, S.; Phisalphong, C.; Ambudkar, S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem., 2007, 296, 85-95.
54. Dennis, T.; Fanous, M.; Mousa, S. Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr. Cancer, 2009, 61, 587-597.
55. Bailey, D.G.; Spence, J.D.; Munoz, C.; Arnold, J.M. Interaction of citrus juices with felodipine and nifedipine. Lancet, 1991, 337, 268-269.
56. Kitagawa, S.; Nabekura, T.; Kamiyama, S. Inhibition of Pglycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol., 2004, 56, 1001-1005.
57. Kitagawa, S.; Nabekura, T.; Takahashi, T.; Nakamura, Y.; Sakamoto, H.; Tano, H.; Hirai, M.; Tsukahara, G. Structure-activity relationships of the inhibitory effects of flavonoids on Pglycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull., 2005, 28, 2274-2278.
58. Kitagawa, S.; Nabekura, T.; Nakamura, Y.; Takahashi, T.; Kashiwada, Y. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. J. Pharm. Pharmacol., 2007, 59, 965-969.
59. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Inhibition of Pglycoprotein function by tannic acid and pentagalloyl glucose. Biochem. Biophys. Res. Commun., 2005, 327, 866-870.
60. Leslie, E.M.; Deeley, R.G.; Cole, S.P.C. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos., 2003, 31, 11-15.
61. Leslie, E.M.; Mao, Q.; Oleschuk, C.J.; Deeley, R.G.; Cole, S.P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol., 2001, 59, 1171-1180.
62. Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with highaffinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev., 2002, 22, 512-529.
63. Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J.M.; Barron, D.; Di Pietro, A. Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. USA, 1998, 95, 9831-9836.
64. Zhou, S.; Lim, L.Y.; Chowbay, B. Herbal modulation of Pglycoprotein. Drug Metab. Rev., 2004, 36, 57-104.
65. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res., 2009, 69, 7507-7511.
66. Chearwae, W.; Anuchapreeda, S.; Nandigama, K.; Ambudkar, S.V.; Limtrakul, P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem. Pharmacol., 2004, 68, 2043-2052.
67. Kunnumakkara, A.B.; Diagaradjane, P.; Anand, P.; Harikumar, K.B.; Deorukhkar, A.; Gelovani, J.; Guha, S.; Krishnan, S.; Aggarwal, B.B. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int. J. Cancer, 2009, 125, 2187-2197.
68. Xue, X.; Yu, J.N.; Sun, D.Q.; Zou, W.; Kong, X.; Wu, J.; Liu, H.P.; Qu, X.J.; Wang, R.M. Curcumin as a multidrug resistance modulator-A quick review. Biomed. Prevent. Nut., 2013, 3, 173-176.
69. Li, X.; Sun, B.; Zhu, C.J.; Yuan, H.Q.; Shi, Y.Q.; Gao, J.; Li, S.J.; Lou, H.X. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycinresistant human myelogenous leukemia (K562/A02) cells. Toxicol. In Vitro, 2009, 23, 29-36.
70. Schumacher, M.; Hautzinger, A.; Rossmann, A.; Holzhauser, S.; Popovic, D.; Hertrampf, A.; Kuntz, S.; Boll, M.; Wenzel, U. Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. Biochem. Pharmacol., 2010, 80, 471-479.
71. Duarte, N.; Lage, H.; Abrantes, M., Ferreira, M.J. Phenolic compounds as selective antineoplasic agents against multidrugresistant human cancer cells. Planta. Med., 2010, 76, 975-980.
72. Chieli, E.; Romiti, N.; Rodeiro, I.; Garrido, G. In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. Chem. Biol. Interact., 2010, 186, 287-294.
73. Nabekura, T.; Yamaki, T.; Hiroi, T.; Ueno, K.; Kitagawa, S. Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol. Res., 2010, 61, 259-263.
74. Nabekura, T.; Yamaki, T.; Ueno, K.; Kitagawa, S. Inhibition of Pglycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother. Pharmacol., 2008, 62, 867-873.
75. Usami, Y.; Goto, K.N.; Lang, J.Y.; Kim Y.; Lai, C.Y.; Goto, M.; Sakurai, N. Antitumor agents 282. 2-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential antibreast and anti-ovarian cancer agent. J. Nat. Prod., 2010, 73, 1553-1558.
76. Wang, S.Q.; Li, X.; Wang, X.N.; Wei, N.N.; Lou, H.X. Coumarins from Cicuta virosa and their modulating effects on multidrugresistant (MDR) tumors. Phytochem. Lettx 2011, 4, 97-100.
77. White, Y.; Hamada, T.; Yoshimitsu, M.; Nakashima, M.; Hachiman, M.; Kozako, T.; Matsushita, K.; Uozumi, K.; Suzuki, S.; Kofune, H.; Furukawa, T.; Arima, N. Novel cytotoxic isolated from Jamaican Hyptis verticillata jacq induces apoptosis and overcomes multidrug resistance. Anticancer Res., 2011, 31, 4251-4257.
78. Chieli, E.; Romiti, N.; Zampini, I.C.; Garrido, G.; Isla, M.I. Effects of Zuccagnia punctata extract and their flavonoids on the function and expression of ABCB1/P-glycoprotein multidrug transporter. J. Ethnopharmacol., 2012, 144, 797-801.
79. Tan, K.W.; Li, Y.; Paxton, J.W.; Birch, N.P.; Scheepens, A. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem., 2013, 138, 2267-2274.
80. An, G.; Gallegos, J.; Morris, M.E. The bioflavonoid kaempferol is an ABCG2 substrate and inhibits ABCG2-mediated quercetin efflux. Drug Metab. Dispos., 2011, 39, 426-432.
81. An, G.; Morris, M.E. The sulphated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharm. Drug Dispos., 2011, 32, 446-457.
82. Christensen, L.P. Aliphatic C(17)-polyacetylenes of the falcarinol type as potential health promoting compounds in food plants of the Apiaceae family. Rec. Pat. Food Nut. Agric., 2011, 3, 64-77.
83. Duarte, R.A.; Mello, E.R.; Araki, C.; Bolzani Vda, S.; Siqueira e Silva, D.H.; Regasini, L.O.; Silva, T.G.; De Morais, M.C.; Ximenes, V.F.; Soares, C.P. Alkaloids extracted from Pterogyne nitens induce apoptosis in malignant breast cell line. Tumour Biol., 2010, 31, 513-522.
84. Regasini, L.O.; Castro-Gamboa, I.; Silva, D.H.; Furlan, M.; Barreiro, E.J.; Ferreira, P.M.; Pessoa, C.; Lotufo, L.V.; De Moraes, M.O.; Young, M.C.; Bolzani Vda, S. Cytotoxic guanidine alkaloids from Pterogyne nitens. J. Nat. Prod., 2009, 72, 473-476.
85. Tajimaa, Y.; Nakagawa, H.; Tamura, A.; Kadioglu, O.; Satake, K.; Mitani, Y.; Murase, H.; Regasini, L.O.; Bolzani, V.S.; Ishikaw, T.; Fricker, G.; Efferth, T. Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine, 2014, 21, 323-332.
86. Wink, M.; Ashour, M.L.; El-Readi, M.Z. Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents. Front. Microbiol., 2013, 3, 130.
87. Eid, S.Y.; El-Readi, M.Z.; Wink, M. Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells. Phytomedicine, 2012, 29, 288-1297.
88. Eid, S.Y.; El-Readi, M.Z.; Wink, M. Digitonin synergistically enhances the cytotoxicity of plant secondary metabolites in cancer cells. Phytomedicine, 2012, 19, 1307-1314.
89. Eid, S.Y, El-Readi, M.Z.; Eldin, E.E.M.N.; Fatani, S.H.; Wink, M. Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells. Phytomedicine, 2013, 21, 47-61.
90. Borska, S.; Chmielewska, M.; Wysocka, T.; Drag-Zalesinska, M.; Zabel, M.; Dziegiel, P. In vitro effect of quercetin on human gastric carcinoma: Targeting cancer cells death and MDR. Food Chem. Toxicol., 2012, 50, 3375-3383.
91. Munagala, S.; Sirasani, G.; Kokkonda, P.; Phadke, M.; Krynetskaia, N.; Lu, P.; Sharom, F.J.; Chaudhury, S.; Abdulhameed, M.D.; Tawa, G.; Wallqvist, A.; Martinez, R.; Childers, W.; Gharbia, M.B.; Krynetskiy, E.; Andrade, R.B. Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorg. Med. Chem., 2014, 22, 1148-1155.
92. Garcia-Carbonero, R.; Supko, J.G.; Maki, R.G.; Manola, J.; Ryan, D.P.; Harmon D.; Puchalski, T.A.; Goss, G.; Seiden, M.V.; Waxman, A.; Quigley, M.T.; Lopez, T.; Sancho, M.A.; Jimeno, J.; Guzman, C.; Demetri, G.D. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J. Clin. Oncol., 2005, 23, 5484-5492.
93. Bai, R.; Edler, M.C.; Bonate, P.L.; Copeland, T.D.; Pettit, G.R.; Luduena, R.F.; Hamel, E. Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: Correlation with cytotoxicity. Mol. Pharmacol., 2009, 75, 218-226.
94. Barr, P.M.; Lazarus, H.M.; Cooper, B.W.; Schluchter, M.D.; Panneerselvam, A.; Jacobberger, J.W.; Hsu, J.W.; Janakiraman, N.; Simic, A.; Dowlati, A.; Remick, S.C. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol., 2009, 84, 484-487.
95. Martin-Algarra, S.; Espinosa, E.; Rubio, J.; Lopez Lopez, J.J.; Manzano, J.L.; Carrion, L.A.; Plazaola, A.; Tanovic, A.; Paz-Ares, L. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur. J. Cancer, 2009, 45, 732-735.
96. Shi, Z.; Jain, S.; Kim, I.W.; Peng, X.X.; Abraham, I.; Youssef, D.T.; Fu, L.W.; El Sayed, K.; Ambudkar, S.V.; Chen, Z.S. Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Cancer Sci., 2007, 98, 1373-1380.
97. Jain, S.; Laphookhieo, S.; Shi, Z.; Fu, L.W.; Akiyama, S.; Chen, Z.S.; Youssef, D.T.; van Soest, R.W.; El Sayed, K.A. Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. J. Nat. Prod., 2007, 70, 928-931.
98. Jain, S.; Abraham, I.; Carvalho, P.; Kuang, Y.H.; Shaala, L.A.; Youssef, D.T.; Avery, M.A.; Chen, Z.S.; El Sayed, K.A. Sipholane triterpenoids: Chemistry, reversal of ABCB1/P-glycoproteinmediated multidrug resistance, and pharmacophore modelling. J. Nat. Prod., 2009, 72, 1291-1298.
99. Abraham, I.; Jain, S.; Wu, C.P.; Khanfar, M.A.; Kuang, Y.; Dai, C.L.; Shi, Z.; Chen, X.; Fu, L.; Ambudkar, S.V.; El Sayed, K.; Chen, Z.S. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochem. Pharmacol., 2010, 80, 1497-1506.
100. Lopez, D.; Martinez-Luis, S. Marine natural products with pglycoprotein inhibitor properties. Mar. Drugs, 2014, 12, 525-546.
101. Li, C.; Sun, B.Q.; Gai, X.D. Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours. Clin. Transl. Oncol2014, 16, 593-598.
102. Fu, L.W.; Zhang, Y.M.; Liang, Y.J.; Yang, X.P.; Pan, Q.C. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur. J. Cancer, 2002, 38, 418-426.
103. Liu, D.L.; Bu, H.; Li, H.; Chen, H.; Guo, H.C.; Wang, Z.H.; Tong, H.F.; Ni, Z.L.; Liu, H.B.; Lin, S.Z. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro. Int. J. Oncol., 2012, 40, 1049-1057.
104. Kwon, H.Y.; Kim, E.H.; Kim, S.W.; Kim, S.N.; Park, J.D.; Rhee, D.K. Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation. Arch. Pharm. Res., 2008, 31, 171-177.
105. Liu, L.; Zuo, L.F.; Guo, J.W. Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line. Oncol. Lett., 2013, 6, 1475-1481.
106. Xu, D.; Lu, Q.; Hu, X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett., 2006, 243, 274-280.
107. Yang, L.; Wei, D.D, Chen, Z.; Wang, J.S.; Kong, L.K. Reversal of multidrug resistance in human breast cancer cells by Curcuma wenyujin and Chrysanthemum indicum. Phytomedicine, 2011, 18, 710-718.
108. Zhang, D.M.; Shu, C.; Chen, J.J.; Sodani, K.; Wang, J.; Bhatnagar, J.; Lan, P.; Ruan, Z.X.; Xiao, Z.J.; Ambudkar, S.V.; Chen, W.M.; Chen, Z.S.; Ye, W.C. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol. Pharm., 2012, 9, 3147-3159.
109. Zheng, Y.; Zhou, F.; Wu, X.; Wen, X.; Li, Y.; Yan, B.; Zhang, J.; Hao, G.; Ye, W.; Wang, G. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J. Ethnopharmacol., 2010, 128, 615-622.
110. Wang, T.H.; Wan, J.Y.; Gong, X.; Li, H.Z.; Cheng, Z. Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Oncol. Rep., 2012, 28, 1681-1686.
111. Li, G.Y.; Liu, J.Z.; Zhang, B.; Yang, M.; Chen, S.G.; Hou, M.; Wang, L.X. Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice. Adv. Med. Sci., 2013, 58, 112-117.
112. Qi, F.; Li, A.; Inagaki, Y.; Gao, J.; Li, J.; Kokudo, N.; Li, X.K.; Tang, W. Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer. Biosci. Trends., 2010, 4, 297-307.
113. Qi, J.; Yang, C.Z.; Wang, C.Y.; Wang, S.B.; Yang, M.; Wang, J.H. Function and mechanism of pyronaridine: a new inhibitor of Pglycoprotein-mediated multidrug resistance. Acta Pharmacol. Sin., 2002, 23, 544-550.
114. Riffkin, C.D.; Chung, R.; Wall, D.M.; Zalcberg, J.R.; Cowman, A.F.; Foley, M.; Tilley, L. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem. Pharmacol., 1996, 52, 1545-1552.
115. Tsuruo, T.; Iida, H.; Kitatani, Y.; Yokota, K.; Tsukagoshi, S.; Sakurai, Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer Res., 1984, 44, 4303-4307.
116. Vezmar, M.; Georges, E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem. Pharmacol., 2000, 59, 1245-1252.
117. Wu, C.P.; Klokouzas, A.; Hladky, S.B.; Ambudkar, S.V.; Barrand, M.A. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochem. Pharmacol., 2005, 70, 500-510.
118. Woehlecke, H.; Osada, H.; Herrmann, A.; Lage, H. Reversal of breast cancer resistance protein mediated drug resistance by tryprostatin A. Int. J. Cancer, 2003, 107, 721-728.
119. Yu, S.T.; Chen, T.M.; Tseng, S.Y.; Chen, Y.H. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun., 2007, 358, 79-84.